Clinical Characteristics of COVID-19-Related Reversible Cerebral Vasoconstriction Syndrome: A Systematic Review of Case Series

Overview

Journal J Clin Med

Date 2025 Jan 25

PMID 39860493

Authors

Raon Jung

Yun-Seo Oh

Soyoun Choi

Moo-Seok Park

Hee-Jung Ha

Na Young Kim

Sohee Wang

Hosseini Seyedehmahla

Yoonkyung Chang

Tae-Jin Song

Affiliations

Soon will be listed here.

Abstract

Although reversible cerebral vasoconstriction syndrome (RCVS) is a rare disease, the condition may occur with COVID-19 infection. We aimed to investigate the clinical characteristics of RCVS through a systematic review of case reports and case series that reported on COVID-19-related RCVS. : A literature search was performed in PubMed (MEDLINE), SCOPUS, and Web of Science. The search was confined to articles published between 17 November 2019 and 14 August 2024. The search terms were ("COVID-19" OR "SARS CoV-2") AND ("RCVS" OR "Reversible cerebral vasoconstriction syndrome"). The search protocol was registered in PROSPERO (CRD42024491818). A total of twenty-four cases were included, nine case series consisting of nineteen cases and five cases from our hospital. Clinical characteristics were investigated, including risk factors, symptoms, brain and angiographic findings, treatment options, and prognoses. The average age was 37.1 years, and females comprised 70.8% of the cohort. COVID-19 vaccination was administered in five cases. Vasoconstriction was most frequently noted in middle cerebral arteries (90.9%). Among the included patients, 12 (50.0%) experienced strokes as a complication of RCVS, and the mortality rate was 9.1%. Follow-up imaging findings were available for 14 of the 24 cases (58.3%). Among these, vasoconstriction was fully improved in 64.3%, partially improved in 28.6%, and aggravated in 7.1%. While the recovery rate of vasoconstriction on brain angiographic findings was not uncommon, our systematic review indicates a potential for a relatively poor neurological prognosis in COVID-19-related RCVS.

References

Quesada J, Lopez-Pineda A, Gil-Guillen V, Arriero-Marin J, Gutierrez F, Carratala-Munuera C . Incubation period of COVID-19: A systematic review and meta-analysis. Rev Clin Esp (Barc). 2021; 221(2):109-117. PMC: 7698828. DOI: 10.1016/j.rceng.2020.08.002. View

Ray S, Kamath V, Raju P A, Kn R, N S . Fulminant Reversible Cerebral Vasoconstriction Syndrome in Breakthrough COVID 19 Infection. J Stroke Cerebrovasc Dis. 2021; 31(2):106238. PMC: 8616734. DOI: 10.1016/j.jstrokecerebrovasdis.2021.106238. View

Spadaro A, Scott K, Koyfman A, Long B . Reversible cerebral vasoconstriction syndrome: A narrative review for emergency clinicians. Am J Emerg Med. 2021; 50:765-772. DOI: 10.1016/j.ajem.2021.09.072. View

Alimohamadi Y, Sepandi M, Taghdir M, Hosamirudsari H . Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg. 2020; 61(3):E304-E312. PMC: 7595075. DOI: 10.15167/2421-4248/jpmh2020.61.3.1530. View

Bridwell R, Long B, Gottlieb M . Neurologic complications of COVID-19. Am J Emerg Med. 2020; 38(7):1549.e3-1549.e7. PMC: 7229718. DOI: 10.1016/j.ajem.2020.05.024. View

Choi H, Lee M, Choi H, Chung C . Characteristics and demographics of reversible cerebral vasoconstriction syndrome: A large prospective series of Korean patients. Cephalalgia. 2017; 38(4):765-775. DOI: 10.1177/0333102417715223. View

Miller T, Shivashankar R, Mossa-Basha M, Gandhi D . Reversible Cerebral Vasoconstriction Syndrome, Part 1: Epidemiology, Pathogenesis, and Clinical Course. AJNR Am J Neuroradiol. 2015; 36(8):1392-9. PMC: 7964694. DOI: 10.3174/ajnr.A4214. View

Pham H, Gosselin-Lefebvre S, Pourshahnazari P, Yip S . Recurrent thunderclap headaches from reversible cerebral vasoconstriction syndrome associated with duloxetine, xylometazoline and rhinitis medicamentosa. CMAJ. 2020; 192(45):E1403-E1406. PMC: 7669296. DOI: 10.1503/cmaj.201234. View

Scheer M, Harder A, Wagner S, Ibe R, Prell J, Scheller C . Case report of a fulminant non-aneurysmal convexity subarachnoid hemorrhage after COVID-19. Interdiscip Neurosurg. 2021; 27:101437. PMC: 8628370. DOI: 10.1016/j.inat.2021.101437. View

10.

Song T, Lee K, Li H, Kim J, Chang K, Kim S . Reversible cerebral vasoconstriction syndrome: a comprehensive systematic review. Eur Rev Med Pharmacol Sci. 2021; 25(9):3519-3529. DOI: 10.26355/eurrev_202105_25834. View

11.

Noguchi S, Miyaoka R, Miyachi H . Clinical Images: Symmetrical Gyriform Restricted Diffusion in Severe Reversible Cerebral Vasoconstriction Syndrome. World Neurosurg. 2023; 177:86-87. DOI: 10.1016/j.wneu.2023.06.042. View

12.

Harapan B, Yoo H . Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J Neurol. 2021; 268(9):3059-3071. PMC: 7826147. DOI: 10.1007/s00415-021-10406-y. View

13.

Singhal A, Hajj-Ali R, Topcuoglu M, Fok J, Bena J, Yang D . Reversible cerebral vasoconstriction syndromes: analysis of 139 cases. Arch Neurol. 2011; 68(8):1005-12. DOI: 10.1001/archneurol.2011.68. View

14.

Alene M, Yismaw L, Assemie M, Ketema D, Gietaneh W, Birhan T . Serial interval and incubation period of COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021; 21(1):257. PMC: 7948654. DOI: 10.1186/s12879-021-05950-x. View

15.

Durrleman C, Naggara O, Grevent D, Belot A, Desgranges M, Boyer O . Reversible cerebral vasoconstriction syndrome in paediatric patients with systemic lupus erythematosus: implications for management. Dev Med Child Neurol. 2018; 61(6):725-729. DOI: 10.1111/dmcn.14031. View

16.

Ahmad I, Rathore F . Neurological manifestations and complications of COVID-19: A literature review. J Clin Neurosci. 2020; 77:8-12. PMC: 7200361. DOI: 10.1016/j.jocn.2020.05.017. View

17.

Sattar A, Manousakis G, Jensen M . Systematic review of reversible cerebral vasoconstriction syndrome. Expert Rev Cardiovasc Ther. 2010; 8(10):1417-21. PMC: 3020907. DOI: 10.1586/erc.10.124. View

18.

Ursell M, Marras C, Farb R, Rowed D, Black S, Perry J . Recurrent intracranial hemorrhage due to postpartum cerebral angiopathy: implications for management. Stroke. 1998; 29(9):1995-8. DOI: 10.1161/01.str.29.9.1995. View

19.

Lee M, Cha J, Choi H, Woo S, Kim S, Wang S . Blood-brain barrier breakdown in reversible cerebral vasoconstriction syndrome: Implications for pathophysiology and diagnosis. Ann Neurol. 2017; 81(3):454-466. DOI: 10.1002/ana.24891. View

20.

Dakay K, Kaur G, Gulko E, Santarelli J, Bowers C, Mayer S . Reversible cerebral vasoconstriction syndrome and dissection in the setting of COVID-19 infection. J Stroke Cerebrovasc Dis. 2020; 29(9):105011. PMC: 7274589. DOI: 10.1016/j.jstrokecerebrovasdis.2020.105011. View